Merck (MRK) closed the most recent trading day at $119.43, moving +0.45% from the previous trading session. The stock's change was more than the S&P 500's daily gain of 0.22%. Meanwhile, the Dow gained 0.36%, and the Nasdaq, a tech-heavy index, added 0.32%.Heading into today, shares of the pharmaceutical company had gained 10.39% over the past month, outpacing the Medical sector's gain of 2.3% and the S&P 500's gain of 1.61% in that time.The investment community will be paying close attention to the earning ...

RAHWAY, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, will hold its fourth-quarter and full-year 2023 sales and earnings conference call with institutional investors and analysts at 9:00 a.m. ET on Thursday, Feb. 1. During the call, company executives will provide an overview of Merck’s performance for the fourth quarter and outlook for 2024. Investors, journalists and the general public may access a live audio webcast of the call via this weblink. A replay ...

More veterinary professionals are provided access to and are pursuing mental health resources for their overall wellbeing with continued improvements on the horizon RAHWAY, N.J., Jan. 15, 2024 /PRNewswire/ -- Merck Animal Health, known as MSD Animal Health outside the United States and Canada, a division of Merck & Co., Inc., Rahway, N.J., USA (NYSE:MRK), today released findings of its comprehensive Veterinary Wellbeing Study conducted in collaboration with the American Veterinary Medical Association (AVMA) ...

RAHWAY, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the U.S. Food and Drug Administration (FDA) has approved KEYTRUDA, Merck’s anti-PD-1 therapy, in combination with chemoradiotherapy (CRT) for the treatment of patients with FIGO (International Federation of Gynecology and Obstetrics) 2014 Stage III-IVA cervical cancer. The approval is based on data from the Phase 3 KEYNOTE-A18 trial, in which KEYTRUDA plus CRT demonstrated an improvement i ...

Merck (MRK) announced a definitive agreement to acquire Harpoon Therapeutics (HARP) for an approximate total equity value of $680 million.The acquisition will strengthen Merck’s oncology pipeline by adding south San Francisco-based Harpoon Therapeutics’ novel class of T cell engagers, which it is developing by leveraging its proprietary Tri-specific T cell Activating Construct platform. The T cell engagers are designed to remain inactive till they reach the tumor.The company has made significant progress in ...

JP Morgan Healthcare Conference Strategy and Business Update Rob Davis Chairman and Chief Executive Officer Forward-looking statement of Merck & Co., Inc., Rahway, N.J., USA ...

Start Time: 19:30 January 1, 0000 8:10 PM ET Merck & Co., Inc. (NYSE:MRK) JPMorgan 42nd Annual Healthcare Conference January 08, 2024, 19:30 PM ET Company Participants Rob Davis - Chairman and CEO Dean Li - President, Merck Research Labs Conference Call Participants Chris Schott - JPMorgan Chris Schott Good afternoon, everybody. I'm Chris Schott at JPMorgan, and it's my pleasure to be introducing Merck today. From the company, we have Rob Davis, Chairman and CEO; as well as Dean Li, President of Merck Resea ...

Start Time: 19:30 January 1, 0000 8:10 PM ET Merck & Co., Inc. (NYSE:MRK) JPMorgan 42nd Annual Healthcare Conference January 08, 2024, 19:30 PM ET Company Participants Rob Davis - Chairman and CEO Dean Li - President, Merck Research Labs Conference Call Participants Chris Schott - JPMorgan Chris Schott Good afternoon, everybody. I'm Chris Schott at JPMorgan, and it's my pleasure to be introducing Merck today. From the company, we have Rob Davis, Chairman and CEO; as well as Dean Li, President of Merck Resea ...

Merck (MRK) closed at $117.38 in the latest trading session, marking a +0.14% move from the prior day. The stock fell short of the S&P 500, which registered a gain of 1.41% for the day. Elsewhere, the Dow saw an upswing of 0.58%, while the tech-heavy Nasdaq appreciated by 2.2%.Heading into today, shares of the pharmaceutical company had gained 12.98% over the past month, outpacing the Medical sector's gain of 6.57% and the S&P 500's gain of 2.9% in that time.Analysts and investors alike will be keeping a cl ...

The shares of Merck & Co Inc (NYSE:MRK) are already 7.3% higher since the start of the year, and earlier hit a six-month high of $117.89 before turning lower. The pharma stock has been on an uptrend since bouncing off familiar support at the $100 level in late November, and just inched into positive territory year over year. The stock's rally could have legs, too, as its recent highs come amid historically low implied volatility (IV), which has been a bullish combination in the past. Per Schaeffer's Quantit ...